What's new in

Pharma

Biotech

🔥 Celcuity's First-Ever Drug Cut Breast-Cancer Progression 76% — and Wall Street Sold It Anyway

Celcuity's first FDA drug, REVTORPYK, cut breast-cancer progression risk 76% and stretched median control from 2.0 to 9.3 months — yet the stock slid on a delayed launch and rough side effects.

Biotech

🔥 Lilly's Triple-Threat Shot Just Melted 55 Pounds — and Notched Its Fifth Phase 3 Win

Eli Lilly's triple-agonist shot retatrutide hit 22.6% weight loss in two more Phase 3 trials — its fifth straight win, with an FDA filing due Q1 2027.

Biotech

🔥 Merck Just Turned a $600-a-Month Injection Into a $315 Pill — and Cut Cholesterol 59%

Merck's Lipfendra (enlicitide) is the first oral PCSK9 inhibitor — a once-daily pill that cuts LDL up to 59%, matching the injectables at $315 a month.